$WORX

SCWorx Corp. (WORX): Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

SCWorx Corp. (WORX) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Summary Company Completed Offering to Cure Nasdaq Publicly Held Shares Deficiency and Submitted Request for Reconsideration; Common Stock Continues to Be Quoted on OTCQB

Original reporting
Published Sep 23, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$WORX
Bearish
medium confidence
Mentioned
$WORX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WORXBearishMed
01

Why it matters

The company completed a private placement intended to cure the publicly held shares shortfall and requested reconsideration of the Panel’s delisting decision, but the Panel decision remains pending and Nasdaq delisting mechanics are described as likely after appeal periods lapse.

02

Market read

Traders should focus on listing-status probability, liquidity expectations on OTCQB, and the remaining compliance timeline tied to the Oct. 5 $1.00 bid-price test.

03

What to watch

Even with reconsideration, the company still must meet the $1.00 closing bid price for 10 consecutive trading days by Oct. 5, and the stock is already suspended on Nasdaq, which can depress liquidity and make compliance harder.

Relevance 7/10Novelty 6/10Timing: Filed today, with reconsideration pending and a compliance deadline of Oct. 5, 2026.

Background

WORX has been suspended on Nasdaq since April 14, 2026, and previously used a 1-for-12 reverse split to address the bid-price rule, but that action triggered a publicly held shares deficiency.

Company-level read

Ticker impact

$WORXBearishMedium confidence
Context

SCWorx says it cured Nasdaq’s publicly held shares deficiency via a Sept. 16 private placement, but the Nasdaq Hearings Panel still ordered delisting pending reconsideration.

Expected impact

Elevated volatility likely, with downside skew if reconsideration fails or if Oct. 5 bid-price compliance is not met; OTCQB quotation may cap liquidity but not remove headline-driven moves.

Evidence & confidence

The filing centers on a delisting decision, a pending reconsideration request, and a specific remaining compliance hurdle (10 consecutive days with a $1.00 close by Oct. 5).

Market effects

Limited direct sector read-across, but it highlights ongoing Nasdaq compliance fragility for microcaps reliant on reverse splits and equity raises.

Primarily US microcap liquidity and listing-status risk; may affect OTCQB trading flows for similar issuers.

Low; this is a US exchange listing compliance event.

Counterpoint

If the Panel accepts the “mistake of material fact” argument that the private placement was completed before the delisting decision, the delisting risk could fade quickly and the stock could re-rate on renewed Nasdaq prospects.

Key entities

  • SCWorx Corp.

    Nasdaq-listed issuer currently quoted on OTCQB, facing delisting risk and seeking reconsideration based on a completed private placement.

  • Nasdaq Hearings Panel

    Issued a delisting decision, stating the reverse split caused failure to meet the publicly held shares rule.

  • Nasdaq Listing Qualifications Staff

    Issued an additional staff determination letter noting the publicly held shares deficiency after the reverse split.

Related articles

$WORXHigh

SCWorx Announces Resumption of Nasdaq Trading and Highlights Improved Operating Performance and Growth Strategy

SCWorx Corp. (Nasdaq: WORX) resumed trading on Nasdaq after regaining compliance with listing requirements. The company reported improved operating performance, with Q2 2026 revenue of $706,000 and gross profit up 83% YoY. Net loss declined significantly, and cash usage decreased. SCWorx aims to grow its healthcare customer base and leverage AI for data management.

Med

SCWorx Corp.: SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company's Continued Listing on the Nasdaq Capital Market

SCWorx Corp. said Nasdaq’s Hearings Panel issued a partial compliance letter confirming completion of the first benchmark in its approved plan to regain compliance for continued listing. The remaining requirement is to meet the Nasdaq minimum bid price of at least $1.00 for 20 consecutive trading days, under Listing Rule 5815(c)(4).